PROCEPT BioRobotics Posts 19% Revenue Growth on Strong HYDROS Adoption
Event summary
- PROCEPT BioRobotics reported $94.5M in Q2 2026 revenue, up 19% YoY.
- Delivered 65 HYDROS systems, including 14 replacements, at an average price of $495K.
- U.S. procedures rose 21% YoY to over 13,100 in Q2 2026.
- Gross margin improved to 66%, up from 65% in the prior year period.
- Completed enrollment in WATER IV prostate cancer study and received updated guideline recommendation.
The big picture
PROCEPT BioRobotics continues to strengthen its position in urology robotics, leveraging AI and real-time imaging to treat benign prostatic hyperplasia (BPH). The company's strategic focus on HYDROS system placements and pricing discipline is driving revenue growth amid a competitive medical device landscape. With $231M in cash reserves as of Q2 2026, PROCEPT appears well-positioned for further expansion.
What we're watching
- Market Penetration
- Whether PROCEPT can sustain its 21% YoY procedure growth in the U.S. market.
- Product Adoption
- The pace at which HYDROS systems replace legacy AquaBeam installations.
- Regulatory Impact
- How the updated American Urological Association guidelines will influence adoption rates.
Related topics